Please login to the form below

BMS appoints Elliott Sigal to Board

Bristol-Myers Squibb has appointed Dr Elliott Sigal to its Board of Directors and to the Board's science and technology committee

Bristol-Myers Squibb (BMS) has appointed Dr Elliott Sigal to its Board of Directors and to the Board's science and technology committee.

Sigal joined BMS in 1997 as vice president of applied genomics. He has since served in critical leadership roles within R&D, including drug discovery and development. During Sigal's time as chief scientific officer, BMS achieved eight new drug approvals and filled the drug pipeline with numerous mid- and late-stage assets, five of which could be approved by 2012.

"We are very excited to have Elliott join our Board," said James M Cornelius, chairman, Bristol-Myers Squibb. "Under his leadership, our R&D organisation has become one of the most productive in the industry. Today's appointment recognises his great contribution to the company."

Sigal has held the role of executive vice president, chief scientific officer and president, BMS research and development since 2004. He reports to Lamberto Andreotti, CEO, BMS.

2nd March 2011

PME Digital Edition

Featured jobs

Senior Brand Manager - Harlow: Competitive
Sales Manager - Media Publishing – Cheshire: 25,000 to 35,000 per annum
UK Marketing Director: 80,000 to 100,000 per annum
Group Account Director –Healthcare Advertising: Neg

Clinical trial regulation in Mexico: Regulatory improvements make Mexico an appealing destination for clinical trials outsourcing...
How can pharma deliver returns on increased digital investment?: Independent online professional networks work best as part of a multi-channel campaign ...
The impact of Hollande's healthcare reforms in France: A tougher environment for pharma, with market access and regulatory challenges...